Wang et al., 2020 shows that inhibiting MIF activity in vivo displayed synergistic antitumor activity with proteasome inhibitors and resensitized PI-resistant MM cells to treatment. The role in the response to PIs of the NRF2, which is one of the key components of cellular response to oxidative stress, has been described in Section 7.1. The gene discussed is MIF; the disease is Miyoshi myopathy.